Hardy Alexander 4

What Happened

• Alexander Hardy, Chief Executive Officer of BioMarin Pharmaceutical (BMRN), disposed of 4,252 shares on March 17, 2026. The filing reports these shares were withheld to satisfy tax obligations (transaction code F) at a reported price of $56.05 per share, totaling about $238,325. This is a tax-withholding disposition rather than an open-market sale.

Key Details

• Transaction date: 2026-03-17; Filing date: 2026-03-19 (appears timely under Form 4 reporting rules).
• Shares involved: 4,252 shares withheld/surrendered.
• Price reported: $56.05 per share; aggregate value reported: $238,325.
• Transaction code: F — indicates shares were used to pay tax withholding (commonly follows option exercise or restricted stock vesting).
• Shares owned after the transaction: not specified in the excerpt of the filing.
• No 10b5-1 plan or other special plan was indicated in this filing excerpt.

Context

• Code F transactions typically reflect withholding to cover taxes upon exercise of options or vesting of restricted stock. They are administrative actions that reduce the insider’s outstanding share count but do not necessarily indicate a decision to take market exposure. For retail investors, purchases or open-market sales can be more informative about insider sentiment than routine tax-withholding dispositions.